Yves Fradet
Cited by
Cited by
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ...
New England Journal of Medicine 376 (11), 1015-1026, 2017
PCA3: a molecular urine assay for predicting prostate biopsy outcome
IL Deras, SMJ Aubin, A Blase, JR Day, S Koo, AW Partin, WJ Ellis, ...
The Journal of urology 179 (4), 1587-1592, 2008
Genomic hallmarks of localized, non-indolent prostate cancer
M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ...
Nature 541 (7637), 359-364, 2017
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
LS Marks, Y Fradet, IL Deras, A Blase, J Mathis, SMJ Aubin, AT Cancio, ...
Urology 69 (3), 532-535, 2007
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
VB Lokeshwar, T Habuchi, HB Grossman, WM Murphy, SH Hautmann, ...
Urology 66 (6), 35-63, 2005
PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata: associations with localized stage progression
BA Inman, TJ Sebo, X Frigola, H Dong, EJ Bergstralh, I Frank, Y Fradet, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
Photodynamic diagnosis of non–muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data
M Burger, HB Grossman, M Droller, J Schmidbauer, G Hermann, ...
European urology 64 (5), 846-854, 2013
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA
SA Tomlins, SMJ Aubin, J Siddiqui, RJ Lonigro, L Sefton-Miller, S Miick, ...
Science translational medicine 3 (94), 94ra72-94ra72, 2011
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 years of follow-up
Y Fradet, J Bellmunt, DJ Vaughn, JL Lee, L Fong, NJ Vogelzang, ...
Annals of Oncology 30 (6), 970-976, 2019
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes
RK Lee, H Abol‐Enein, W Artibani, B Bochner, G Dalbagni, ...
Wiley Periodicals, Inc., 2014
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma
ME Gleave, M Elhilali, Y Fradet, I Davis, P Venner, F Saad, LH Klotz, ...
New England journal of medicine 338 (18), 1265-1271, 1998
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III …
Y Fradet, HB Grossman, L Gomella, S Lerner, M Cookson, D Albala, ...
The Journal of urology 178 (1), 68-73, 2007
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ...
European urology 66 (5), 815-825, 2014
Widespread and functional RNA circularization in localized prostate cancer
S Chen, V Huang, X Xu, J Livingstone, F Soares, J Jeon, Y Zeng, JT Hua, ...
Cell 176 (4), 831-843. e22, 2019
Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy …
JC Nickel, Y Fradet, RC Boake, PJ Pommerville, JP Perreault, SK Afridi, ...
CMAJ: Canadian Medical Association Journal 155 (9), 1251, 1996
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.
Y Fradet, C Cordon-Cardo, T Thomson, ME Daly, WF Whitmore Jr, ...
Proceedings of the National Academy of Sciences 81 (1), 224-228, 1984
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with …
HB Grossman, L Gomella, Y Fradet, A Morales, J Presti, C Ritenour, ...
The Journal of urology 178 (1), 62-67, 2007
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer
A Stenzl, M Burger, Y Fradet, LA Mynderse, MS Soloway, JA Witjes, ...
The Journal of urology 184 (5), 1907-1914, 2010
The system can't perform the operation now. Try again later.
Articles 1–20